Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Melanoma 3Colitis 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hepatitis 1Graft vs Host Disease 1

Interventions

pembrolizumab 4Nivolumab 4fludarabine 3aldesleukin 3Ipilimumab 3Cyclophosphamide 3vedolizumab 2enfortumab vedotin 2darolutamide 2cabozantinib 2atezolizumab 2Specimen Handling 2Riluzole 2Prednisone 2Magnetic Resonance Spectroscopy 2LDP-02 2Infliximab 2Immunoglobulin G 2Fecal Microbiota Transplantation 2Disulfides 2CTLA-4 Antigen 2CT-P13 2Biopsy 2relatlimab 1prednylidene 1palbociclib 1olaparib 1gallium 68 PSMA-11 1deltacortene 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urogenital Neoplasms × vedolizumab × 1 year × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡